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Summary A set of monoclonal antibodies was constructed by immunising mice with peptide fragments of
the c-myc oncogene product. One such antibody, Myc 1-6E10 was shown to bind to a 62,000 dalton protein
identifiable with the c-myc product (p62c-mYc). The antigen recognised was not destroyed by paraflin wax
embedding. Myc 1-6E10 was used to characterise the distribution of p62C-fYC in archival testicular tumour
material. Normal testes expressed only small amounts of p62c-mYc. Seminomas showed increased nuclear and
cytoplasmic staining. Undifferentiated teratoma showed little activity, whereas p62c-mYc was abundant in the
nuclei of differentiating epithelial structures, yolk sacs and embryoid bodiesl Only small amounts of p62c-"Yc
were seen in the tumours of 5 patients who subsequently died from their disease.
The demonstration that human cancer cells may
show abnormal expression of unique segments of
DNA, called oncogenes, provides an exciting new
avenue for clinical investigation. Over 25 of these
genes have now been identified, molecularly cloned
and sequenced (Krontiris, 1983; Hamlyn & Sikora,
1983). Changes in the coding or control regions of
these genes have been implicated in the develop-
ment of cancer (Cooper & Lane, 1984; Bishop,
1984). Several molecular mechanisms resulting in
either the increased production of normal oncogene
products or the development of aberrant proteins
that subvert the normal growth control processes
have now been uncovered (Der & Cooper, 1983;
Stewart et al., 1984b). These include gene amplifi-
cation, translocation, mutation and rearrangement.
Such changes have been documented in fresh
tumour biopsies from patients as well as cultured
cell lines (Rothberg et al., 1984; Favera et al.,
1982). Using DNA hybridisation techniques, the N-
myc gene has found to be amplified up to 100-fold
in neuroblastoma (Schwab et al., 1983) and retino-
blastoma (Lee et al., 1984). In one patient with
chronic myelocytic leukaemia, the c-myc sequence
was amplified 16-fold and rearranged within the
genome during episodes of transformation
(McCarthy et al., 1984). Oncogene RNA transcripts
have also been measured in fresh tumour material.
K-ras and H-ras mRNA has been found elevated in
colonic carcinoma, colonic polyps (Spandidos &
Kerr, 1984) and breast cancer (Spandidos &
Agnantis, 1984). Most interest has surrounded the
ras and myc genes as considerable variation has
been found in the quantity of their transcripts in
clinical biopsies at the RNA level (Slamon et al.,
1984).
DNA and RNA hybridisation analysis is difficult
to perform with many clinical samples. Low copy
number genes and message cannot be detected with
current methods. Hybridisation techniques cannot
normally be applied to fixed embedded material
stored in pathology departments. Furthermore they
tell us nothing about the ultimate concentration
and distribution in the cell of the gene product. The
structure and function of these proteins are now
under active investigation. At least one is related to
a growth factor (c-sis) (Waterfield et al., 1983) and
another (c-erb B) to the internal component of the
surface receptor for a growth factor (Downward et
al., 1984). The c-myc gene product is particularly
intriguing with regard to human cancer. There is
now evidence that this protein is associated with
cell division and differentiation. The level of c-myc
RNA increases when cells are stimulated into
division (Kelly et al., 1983). Both mRNA trans-
cripts and the protein itself have unusually short
half-lives of 20 to 30min (Rabbitts et al., 1985), a
prerequisite for their putative cell cycle control
function. Furthermore the protein appears to be
associated with cell nuclei, a likely site for such
control (Pauza & Evan, submitted for publication).
In order to examine the relevance of c-myc in
clinical samples a set of mouse monoclonal anti-
bodies against the c-myc protein was constructed
(Evan et al., 1985). The DNA sequence of the c-
myc gene was used to determine the amino acid
structure of the c-myc oncoprotein. Peptides of
between 10 and 18 amino acids long were syn-
thesized. The regions chosen for synthesis and im-
munisation were predicted to be exposed within
the intact molecule by assessing the relative hydro-
philicity of different parts of the sequence. Mice
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were immunised to produce monoclonal antibodies
(MCAs). Six MCAs were shown to bind to a
62,000 dalton protein identifiable with the c-myc
product (p62c-mYc). These MCAs are currently
being used to isolate and functionally characterise
the c-myc protein.
In this report we demonstrate that one of these
antibodies, Myc 1-6E10, can be used to detect
p62c-mYc protein in archival material from pathology
laboratories. Because of the implication of this
protein in growth and differentiation we chose to
study tumour samples from patients with testicular
cancer. Tumours of the testis arise predominantly
from cells of the germ cell lineage (Ellis & Sikora,
1985). Malignant teratoma tissue often contains a
wide range of differentiated cells identifiable by
light microscopy in addition to undifferentiated and
replicating stem cells. It therefore provides a bio-
logically interesting system in which to examine the
role of p62c-mYc in differentiation as well as being of
clinical interest.
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Patients and methods
Monoclonal antibody
Peptide synthesis, the immunisation protocol and
screening procedures for deriving Myc 1-6E10 are
described elsewhere (Evan et al., 1985) and sum-
marised in Figure 1. Hybridoma cells were grown
in the ascites fluid of female BALB/c mice. The
antibody was purified by octanoic acid precipitation
followed by ammonium sulphate concentration.
Purified antibody was adjusted to a concentration
of 2mgml-1 in PBS with 0.001% sodium azide,
aliquoted and stored at -20°C. A control mouse
immunoglobulin of the same sub-class (IgG1K) was
obtained from ascites fluid of the mouse myeloma
line X-63 (Kohler & Milstein, 1975). It was
similarly purified and adjusted to a concentration
of 2mgml-1.
Immunohistology
Parafflin blocks containing surgical biopsies were
obtained from the archives of the Department of
Pathology. Thirty-two patients attending the Testi-
cular Tumour Clinic at Addenbrooke's Hospital
were studied. Sections (5pm) were cut and placed
on standard microscope slides previously immersed
in a 0.5% gelatin solution which also contained
250mg chrome alum and 30mg sodium azide
100ml-1 and air-dried overnight. An avidin-biotin
technique was used to stain the sections
(Vectorstain ABC Kit, Vector Labs). Sections were
dewaxed and rehydrated using xylene and alcohol,
incubated for 30min with 0.5% hydrogen peroxide
MCA s
Figure 1 Schema for
peptide immunisation.
Synthetic Peptides
Immunisation
the production of MCA by
in methanol, washed and incubated for 20min in
diluted normal serum. Excess serum was blotted
and the sections incubated for 60min with 100p1
Myc 1-6E10 diluted 1/500 in PBS, 1% BSA and
0.25% Triton X-100 (pH 7.3). Sections were
washed and then incubated with a biotinylated
rabbit anti-mouse immunoglobulin. After a further
wash, sections were incubated for 45min with the
Vectorstain ABC reagent. A final incubation in
diaminobenzidine (100mg in 200ml 0.5% hydrogen
peroxide solution) was performed for 30min and
the sections washed with tap water and counter-
stained in Mayer's haemalum for 60sec.
Results
Specificity controls
Most seminomas and teratomas showed consider-
able staining using Myc 1-6E10 when comparedC-MYC IN TESTICULAR CANCER 173
to normal testis. An irrelevant mouse monoclonal
immunoglobulin (X63 IgG) of the same immuno-
globulin subclass showed no binding. Staining by
Myc 1-6E10 was blocked by the addition of 1 yg
of the peptide used as the immunogen added to
100lp of antibody prior to its addition to tumour
sections (Table I).
Table I Specificity controls
First antibody Seminoma Teratoma
Myc 1-6E10 + + + + + +
Myc 1-6E10+Peptide - -
Mouse X63 IgGlk
PBS
Normal testis
Small amounts of p62c-mYc were demonstrated in
the cytoplasm and nuclei of the more peripheral
spermatogonia of the normal seminiferous tubule
(Figure 2a,b). The amount decreased towards the
lumen of the tubules. It was also present in the
cytoplasm of the interstitial cells of Leydig. There
was no variation between different areas of the
same testis.
Seminoma
Eleven patients with seminoma were studied. All
showed increased D62c-myc staining Dredominantlv
a
located in cell nuclei but with some cytoplasmic b
increase. There was considerable variation between
different areas of the same tumour and between Figure 2 Transverse (a) and longitudinal sections (b)
different tumours (Figure 3). Infiltrating lympho- through a seminiferous tubule in a normal testis.
cytes showed little or no staining. p62c-Yc present in small amounts in some spermato- cytes showed little or no staining. gonia (x 400).
Malignant teratoma
There was considerable variation in staining
intensity between different parts of individual
tumours in the 21 teratomas examined. Undif-
ferentiated areas showed little p62c-mYc activity,
ofter less than the basal spermatogonia of normal
testes. Areas of greatest intensity were clustered at
sites of outgrowth of differentiating epithelial
structures (Figure 4ab; Figure 5). Certain tumours,
especially those with yolk sac differentiation,
showed intense staining (Figures 6a,b). Little or no
staining was seen in areas of trophoblastic dif-
ferentiation (Table II).
No correlation of p62c-mYc staining was observed
between the stage of the disease or the preoperative
serum level of human chorionic gonadotrophin.
I-ive patients wno subsequently tied trom tneir
disease, and one who is currently undergoing
chemotherapy for a recurrence, all had small Figure 3 Section of orchidectomy specimen from a
amounts ofthe p62c-mYc in their tumour. patient with stage I testicular seminoma ( x400).174 K. SIKORA et al.
Table II Immunohistological data
Tissue/tumour p62C-MYc distribution
Normal testis Small amounts of nuclear and
cytoplasmic staining in
spermatogonia at periphery of
seminiferous tubules
Seminoma Diffuse nuclear staining; little
variation between tumours; no
lymphocyte uptake
Malignant teratoma:
Differentiated Strong nuclear and cytoplasmic
areas staining in developing epithelial
areas; no staining in fully
differentiated areas
Undifferentiated Little staining
areas
Trophoblastic No staining
Yolk sac Strong nuclear and cytoplasmic
staining in lining cells; especially
prominent in embryoid bodies
Figure 5 p62c-mYc activity in nuclei and cytoplasm in
differentiating areas of another malignant teratoma
intermediate ( x 400).
a
u
Figure 4 Sections through a specimen from a patient
with malignant teratoma intermediate (MTI). p62c-mYc
is most prominent in the nuclei of differentiating cells
at areas of outgrowth (a) x 200 (b) x 400.
b
Figure 6 Embryoid body in patient with yolk sac
malignant teratoma showing high p62'-mYe activity in
lining cells (a) x 200 (b) x 1000.C-MYC IN TESTICULAR CANCER 175
Discussion
The development of monoclonal antibodies to
oncogene products provides essential reagents for
characterising oncoprotein function and distribution
in health and disease. The remarkable conservation
of the DNA sequence of individual oncogenes
across wide reaches of evolutionary time points to
an essential role of their gene products in normal
development. Testicular cancer thus provides a bio-
logically as well as clinically relevant system for
study.
The examination of c-myc mRNA in the
developing human placenta indicates that the peak
of myc transcription occurs at 4-5 weeks after
conception (Pfeifer-Ohlsson et al., 1984). Other
oncogene RNA transcripts have been found to be
elevated in differentiating systems. During liver
regeneration the expression of H-ras and c-myc
genes are increased (Goyette et al., 1983) and the
c-fos gene product is specifically elevated in
developing bone (Muller et al., 1982). In most cells
the level of c-myc mRNA has been found to be low
but increases with the rate of cell division (Pauza &
Evan, submitted for publication). In the normal
dividing germ cells of the mouse testis very few c-
myc mRNA transcripts have been found. The drive
to proliferate, at least for several divisions, may
therefore come from other gene products. By
partially purifying mouse testicular cells it has been
demonstrated that c-myc expression was greatest in
spermatogonia during the process of their dif-
ferentiation into spermatocytes (Stewart et al.,
1984a). The histological studies described here
suggest a similar pattern in normal human testis.
The control of cell division and differentiation
are complex requiring the interaction of many
different molecular mechanisms. The c-myc gene
product is probably involved in both processes.
Normal differentiation of germ cells requires the
transient expression of high quantities of p62c-mYc.
Malignant cells can also arise with several dif-
ferentiation characteristics and containing various
amounts of p62c-mYc. The most undifferentiated
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Figure 7 Model for c-myc expression during normal
spermatogenesis and the development of germ cell
tumours.
and therefore clinically aggressive teratomas contain
low levels of this protein as measured by our
antibody. Tumours can differentiate so expressing
elevated levels, especially those with yolk sac
elements. Fully differentiated tissue reverts to lower
c-myc expression (Figure 7). This model accounts
for the immunohistological observations in
testicular cancer. Studying the expression of
different gene products in histological material may
result in greater precision of diagnosis and
prognosis as well as opening new avenues for future
therapy.
We would like to thank Professors J. Michael Bishop and
Austin Gresham and Drs Sydney Brenner and Derek
Wight for helpful discussion. J.S. holds a CRC
Fellowship.
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